During the past decade, Groupe de Recherche en Rhumatologie et Maladies Osseuses conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 7 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Groupe de Recherche en Rhumatologie et Maladies Osseuses" #1 sponsor was "Pfizer" with 3 trials, followed by "Atrium Innovations" with 1 trials sponsored, "Bioiberica" with 1 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored and "Genentech, Inc." with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Groupe de Recherche en Rhumatologie et Maladies Osseuses" #1 collaborator was "Aliments ULTIMA Foods Inc." with 1 trials as a collaborator and "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Groupe de Recherche en Rhumatologie et Maladies Osseuses" are "Osteoarthritis" (2 trials), "Rheumatoid Arthritis" (2 trials), "Ankylosing Spondylitis" (1 trials), "Arthritis" (1 trials) and "Arthritis, Rheumatoid" (1 trials). Many other conditions were trialed in "Groupe de Recherche en Rhumatologie et Maladies Osseuses" in a lesser frequency.

Most popular intervention types in "Groupe de Recherche en Rhumatologie et Maladies Osseuses" are "Drug" (9 trials), "Dietary Supplement" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "200 g yogurt with fortified calcium content and MBP 80 mg" (1 trials), "Abatacept" (1 trials), "Any oral bisphosphonates marketed in Canada" (1 trials) and "CP-690,550" (1 trials). Other intervention names were less common.

The vast majority of trials in "Groupe de Recherche en Rhumatologie et Maladies Osseuses" are 9 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Groupe de Recherche en Rhumatologie et Maladies Osseuses". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Groupe de Recherche en Rhumatologie et Maladies Osseuses, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Groupe de Recherche en Rhumatologie et Maladies Osseuses, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".